Sugi Predict

Sugi Predict / Compounds / SCHEMBL4586692

SCHEMBL4586692

SCHEMBL4586692

O=C(COC(=O)c1ccccc1)COC(=O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.63
▸ ALDH1A1 P00352 3/20 0.61
▸ L3MBTL1 Q9Y468 2/20 0.61
▸ KDM4E B2RXH2 2/20 0.61
▸ GAA P10253 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ HIF1A Q16665 1/20 0.61
▸ SLC6A2 P23975 1/20 0.61
▸ SLC6A3 Q01959 1/20 0.61
▸ RAB9A P51151 3/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ HPGD P15428 2/20 0.59
▸ LMNA P02545 2/20 0.59
▸ CYP1A2 P05177 1/20 0.58
▸ CYP2C9 P11712 1/20 0.58
▸ CYP2C19 P33261 1/20 0.58
▸ F2 P00734 1/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ NFKB1 P19838 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714123 0.90 TDP1 (0.57) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL3829668 0.88 TDP1 (0.55) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL4523401 0.88 RAB9A (0.57) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL712632 0.88 LMNA (0.61) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL582352 0.86 TDP1 (0.63) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL194520 0.86 TDP1 (0.63) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL7421565 0.85 PTPN1 (0.53) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL27476658 0.85 ALDH1A1 (0.65) TDP1ALDH1A1L3MBTL1KDM4EGAA
SCHEMBL30150476 0.85 LMNA (0.62) TDP1ALDH1A1L3MBTL1KDM4EGAA
Potassium SCHEMBL31360984 0.84 TDP1 (0.61) TDP1ALDH1A1L3MBTL1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016090169-A1 INTRACELLULAR CASPASE PROBES FOR DETECTION OF APOPTOSIS AND INFLAMMATION AND KITS CONTAINING SUCH PROBES SEED RESEARCH AND DEVELOPMENT LLC (US) 2016-06-09 — — WO claimed
US-6833262-B1 For cleavage of denatured polypeptides and nondenatured serpin polypeptides particularly a human alpha 1-proteinase inhibitor UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2004-12-21 — — US claimed
CN-115298180-B Compounds for treating or inhibiting recurrence of acute myeloid leukemia 日本理化学研究所 2025-06-10 — — CN disclosed
US-11963960-B2 Compounds for treating or inhibiting recurrence of acute myeloid leukemia FLASH THERAPEUTICS, LLC (US) 2024-04-23 — — US disclosed
EP-4121430-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA Flash Therapeuttics, LLC (US) 2023-01-25 — — EP disclosed
CN-115298180-A Compounds for treating or inhibiting recurrence of acute myeloid leukemia 富雷旭医疗有限责任公司 2022-11-04 — — CN disclosed
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2021-09-30 — — US disclosed
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2021-09-30 — — US disclosed
WO-2021188417-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA FLASH THERAPEUTICS, LLC (US) 2021-09-23 — — WO disclosed
WO-2021188417-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA FLASH THERAPEUTICS, LLC (US) 2021-09-23 — — WO disclosed
US-9956260-B1 Treatment of HIV-1 infection and AIDS THE J. DAVID GLADSTONE INSTITUTES (US) 2018-05-01 — — US disclosed
US-6576614-B1 Administering methyl ketones or closed hemiketal derivatives of aspartic acid VERTEX PHARMACEUTICALS INCORPORATED 2003-06-10 — — US disclosed
WO-2003016335-A2 IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS OF LEGUMAIN PROBIODRUG AG (DE) 2003-02-27 — — WO disclosed
US-20020150947-A1 Extended tethering approach for rapid identification of ligands SUNESIS PHARMACEUTICALS, INC. 2002-10-17 — — US disclosed
WO-2000063394-A9 A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN UNIV GEORGIA RES FOUND (US) 2002-06-27 — — WO disclosed
WO-2002042773-A2 AN EXTENDED TETHERING APPROACH FOR RAPID IDENTIFICATION OF LIGANDS SUNESIS PHARMACEUTICALS, INC. (US) 2002-05-30 — — WO disclosed
US-6251882-B1 TREATING LEUKEMIA, BREAST CANCER, PROSTATE CANCER, OR BRAIN TUMOR PARKER HUGHES INSTITUTE 2001-06-26 — — US disclosed
EP-1091934-A2 ALKYL KETONES AS POTENT ANTI-CANCER AGENTS Parker Hughes Institute (US) 2001-04-18 — — EP disclosed
WO-2000063394-A2 A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2000-10-26 — — WO disclosed
WO-2000000469-A2 ALKYL KETONES AS POTENT ANTI-CANCER AGENTS PARKER HUGHES INSTITUTE (US) 2000-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11963960-B2 Compounds for treating or inhibiting recurrence of acute myeloid leukemia MCL1, FLT3, ABL1 TDP1 3548/4885ALDH1A1 1260/4885L3MBTL1 299/4885
US-20210299128-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA MCL1, FLT3, ABL1 TDP1 3548/4885ALDH1A1 1260/4885L3MBTL1 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.